Search

Displaying results 9411 - 9420 of 10000 in total
  1. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels

    Categories: Heterocyclic Compounds, 1-Ring
  2. Drug

    MDX-1379

    go.drugbank.com/drugs/DB05329
    Investigational

    MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.

  3. Drug

    TC-5231

    go.drugbank.com/drugs/DB05333
    Experimental

    TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder). … TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine.

  4. Drug

    SOT-107

    go.drugbank.com/drugs/DB05337
    Investigational

    SOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. This drug treat for a type of brain cancer called a high grade glioma brain tumour.

  5. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.

    Synonyms: An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid, Allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid encoding human ciliary neurotrophic factor (CNTF).Categories: Complex Mixtures
  6. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    Compared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery … Dexlansoprazole is the R-enantiomer of [DB00448], which is composed of a racemic mixture of the R- and S-enantiomers.

    Synonyms: (+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE, 1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-Categories: Cytochrome P-450 Substrates, 2-Pyridinylmethylsulfinylbenzimidazoles
  7. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  8. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

    Synonyms: Actelion-1Categories: Endothelin A Receptor Antagonists, Heterocyclic Compounds, 1-Ring
  9. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.

  10. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. … HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.